Blurbs

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Vertex Pharmaceuticals (VRTX) and Tecan Group AG (OtherTCHBF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Exelixis (EXELResearch Report), Vertex Pharmaceuticals (VRTXResearch Report) and Tecan Group AG (TCHBFResearch Report).

Exelixis (EXEL)

In a report issued on July 11, Gregory Renza from RBC Capital maintained a Buy rating on Exelixis, with a price target of $31.00. The company’s shares closed last Tuesday at $21.07.

According to TipRanks.com, Renza is a 1-star analyst with an average return of -4.0% and a 35.8% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Exelixis is a Strong Buy with an average price target of $30.40, implying a 46.6% upside from current levels. In a report issued on July 11, Jefferies also maintained a Buy rating on the stock with a $28.00 price target.

See today’s best-performing stocks on TipRanks >>

Vertex Pharmaceuticals (VRTX)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Vertex Pharmaceuticals on July 11 and set a price target of $269.00. The company’s shares closed last Tuesday at $290.01, close to its 52-week high of $296.84.

According to TipRanks.com, Abrahams is a 3-star analyst with an average return of 1.0% and a 47.3% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Enanta Pharmaceuticals.

Currently, the analyst consensus on Vertex Pharmaceuticals is a Moderate Buy with an average price target of $292.63, a -0.1% downside from current levels. In a report issued on July 5, Robert W. Baird also maintained a Hold rating on the stock with a $250.00 price target.

Tecan Group AG (TCHBF)

In a report issued on July 11, Maja Pataki from Kepler Capital maintained a Buy rating on Tecan Group AG, with a price target of CHF384.00. The company’s shares closed last Tuesday at $330.95, close to its 52-week low of $270.27.

According to TipRanks.com, Pataki is ranked #7785 out of 7912 analysts.

Currently, the analyst consensus on Tecan Group AG is a Moderate Buy with an average price target of $470.97.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EXEL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos